Cristin-resultat-ID: 1780539
Sist endret: 23. januar 2020 09:16
Resultat
Poster
2010

Remission and tumor cell protection in PVG rats by subcutaneous injection of LTX-315 into an aggressive malignant rat mesenchymal tumor with stemness characteristics

Bidragsytere:
  • Gunnar Kvalheim
  • Mengyu Wang
  • Severin Zinöcker
  • Ketil Andre Camilio
  • Bent Rolstad
  • John T. Vaage
  • mfl.

Konferanse

Tittel: ASCO Annual Meeting

Sted:

Chicago
USA
Utbredelsesområde: Internasjonalt
Årstall: 2010
Dato fra: 4. juni 2010
Dato til: 8. juni 2010

Arrangør:

American Society of Clinical Oncology

Om resultatet

Poster
Publiseringsår: 2010

Beskrivelse Beskrivelse

Tittel

Remission and tumor cell protection in PVG rats by subcutaneous injection of LTX-315 into an aggressive malignant rat mesenchymal tumor with stemness characteristics

Sammendrag

Background: LTX-315 (Oncopore) is a chemically designed cationic nonapeptide derived from a natural host defensive CAP, bovine lactoferricin (LfcinB) in development for local treatment of tumours. Earlier studies have demonstrated that treatment of A20 lymphomas and CT26WT carcinomas with LTX-315 in immunocompetent mice resulted in tumour regression. Re-challenge with tumor cells in the cured animals showed that a long- term protection was induced against the tumor. Methods: In the current experiments we have investigated if LTX-315 also can have the same effect on a novel established malignant rat mesenchymal tumor cell line with “stemness” properties. Following long term culturing of bone marrow derived rat mesenchymal cells we developed a rat transformed mesenchymal cell line (rTMSC). Previously we have shown that s.c. as well as i.v. and i.p. injection of rTMSC form immature sarcoma tumors both in nude rats as well as in PVG rats. The rTMSC has been stabled marked with a dual reporter gene GFP and Leuciferase and in the current study CCD camera was used for dynamic living imaging. 5×105 rTMSCs were subcutaneously inoculated into 20 PVG rats. After 7 days measurable tumors could be observed and 18 animals was treated with LTX-315. Results: In spite of repeated injection with the peptide 8 animals lost tumor control, while 9 animals within 38 days achieved complete tumor responses as assessed with CCD camera. Re-challenges of the tumor free animals with injection of 5×104 tRMSCs show no tumor growth while all control animals had a fast tumor formation. Conclusions: 50% of the treated animals have developed an impressive tumor protection of this aggressive mesenchymal tumor with “stemness” properties. Most likely more animals can be cured if the peptide injection procedure can be improved and further studies are underway. Altogether our results bear promises for LTX-315 in future cancer therapy. No significant financial relationships to disclose. © 2010 by American Society of Clinical Oncology

Bidragsytere

Gunnar Kvalheim

  • Tilknyttet:
    Forfatter
    ved Seksjon for celleterapi ved Oslo universitetssykehus HF

Mengyu Wang

  • Tilknyttet:
    Forfatter
    ved Seksjon for tumorbiologi ved Oslo universitetssykehus HF
Aktiv cristin-person

Severin Zinöcker

  • Tilknyttet:
    Forfatter
    ved Avdeling for vurdering av tiltak ved Folkehelseinstituttet

Ketil Andre Camilio

  • Tilknyttet:
    Forfatter
Inaktiv cristin-person

Bent Rolstad

  • Tilknyttet:
    Forfatter
1 - 5 av 7 | Neste | Siste »